Manuscript
Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy
January 10, 2024
The use of immune checkpoint inhibitors (ICI) in patients with bladder cancer (BC) is currently limited. Patients with BC who have experienced loss of the Y chromosome (LOY) often exhibit an aggressive cancer phenotype. In these LOY BC cases, CD8+ T cell exhaustion hampers the development of a robust anti-tumor response. However, there is a subset of patients with LOY BC who may show increased responsiveness to ICIs, suggesting a potential avenue for more effective treatment.
Published in: Advances in Therapy